WO-2026096766-A2 - CANNABINOIDS FOR THE TREATMENT OF CANCER

Abstract

Provided herein are treatments for cancers, such as endometrial cancers. Compositions, methods, and kits are described herein. The treatments described herein for cancers can comprise cannabinoids such as cannabidiol (CBD), cancer therapeutics, terpenes, flavonoids, or combinations thereof.

Inventors

• Spirtos, Nicola Michael

Assignees

• YUZU LV LLC

Dates

Publication Date

20260507

Application Date

20251030

Priority Date

20241030

Claims (20)

1. CLAIMS
2. WHAT IS CLAIMED IS:
3. 1. A method for treating an endometrial cancer in a subject in need thereof comprising administering to the subject in need thereof an effective amount of a formulation comprising:
4. (a) a cannabidiol (CBD), or a salt thereof;
5. (b) a terpene, a salt thereof, a flavonoid, a salt thereof, or any combination thereof;
6. (c) a cancer therapeutic; and
7. (d) an excipient, a carrier, a diluent, or any combination thereof.
8. 2. The method of claim 1, wherein the endometrial cancer comprises an endometrial adenocarcinoma, a uterine carcinoma, a uterine sarcoma, a squamous cell carcinoma, a small cell carcinoma, a transitional carcinoma, a serous carcinoma, a clear cell carcinoma, or any combination thereof.
9. 3. The method of claim 1, wherein the endometrial cancer comprises an endometrial adenocarcinoma.
10. 4. The method of claim 1, wherein the endometrial cancer comprises a clear cell carcinoma.
11. 5. The method of claim 1, wherein the terpene or the salt thereof comprises a P-myrcene, a P-caryophyllene, an ocimene, an a-pinene, an a-humulene, a linalool, a p-cymene, a camphene, a cis-nerolidol, a terpinolene, an isopulegol, a caryophyllene oxide, a 6-limonene, a geraniol, a guaiol, a-bisabolol, a 3-carene, a P-pinene, a y-terpinene, a salt of any of these, or any combination of the foregoing.
12. 6. The method of claim 1, wherein the flavonoid or the salt thereof comprises a naringenin, a naringin, a blumeatin, a butin, an eriodictyol, a hesperetin, a hesperidin, a homoeriodictyol, an isosakuranetin, a pinocembrin, a poncirin, a sakuranetin, a sakuranin, a sterubin, a pinostrobin, a salt of any of these, or any combination of the foregoing.
13. 7. The method of claim 1, wherein the cancer therapeutic comprises a chemotherapy, an non-steroidal anti-inflammatory (NS AID), a platinum analogue, a tyrosine kinase inhibitor, an anthracycline, a taxane, a mTOR and/or AKT targeting therapy, a p53 targeting therapy, a PARP inhibitor, a sphingolipid metabolism targeting therapy, a hormone therapy, a hyperthermia therapy, an immunotherapy, a photodynamic therapy, a radiation therapy, a stem cell therapy, a surgery, or any combination thereof.
14. 8. The method of claim 7, wherein the chemotherapy comprises a 5-fluorouracil, a temozolamide, a 6-mercaptopurine, an azacitidine, a capecitabine, a cladribine, a clofarabine, a cytarabine, a decitabine, a floxuridine, a fludarabine, a gemcitabine, a hydroxyurea, a methotrexate, a nelarabine, a pemetrexed, a pentostatin, a pralatrexate, a thioguanine, a trifluridine/tipiracil, a cabazitaxel, a docetaxel, a nab-paclitaxel, a paclitaxel, a vinblastine, a vincristine, a vincristine liposomal, a vinorelbine, a salt of any of these, or any combination of the foregoing.
15. 9. The method of claim 7, wherein the NSAID comprises an ibuprofen, a naproxen, a diclofenac, a celecoxib, a mefenamic acid, an etoricoxib, an indomethacin, an aspirin, a ketorolac, a diclofenac, a meloxicam, a ketorolac, an esomeprazole, a nabumetone, a indomethacin, a mefenamic acid, a piroxicam, a diclofenac, a diflunisal, a sulindac, a ketoprofen, a tolmetin, a fenoprofen, a salt of any of these, or any combination of the foregoing.
16. 10. The method of claim 7, wherein the platinum analogue comprises an el oxatin, a cisplatin, a carboplatin, an oxaliplatin, a nedaplatin, a lobaplatin, a heptaplatin, a triplatin tetranitrate, a phenathriplatin, a picoplatin, a satraplatin, a salt of any of these, or any combination of the foregoing.
17. 11. The method of claim 7, wherein the tyrosine kinase inhibitor comprises a dasatinib, an imatinib, a gefitinib, an erlotinib, a vemurafenib, a sorafenib, a ponatinib, a nilotinib, a masitinib, an axitinib, a pazopanib, a sunitinib, a salt of any of these, or any combination of the foregoing.
18. 12. The method of claim 7, wherein the anthracycline comprises an adriamycin, a caelyx, a cerubidine, a cytarabine, a daunorubicin, a doxorubicin, an epirubicin, a idarubicin, a mitoxantrone, a pharmorubicin, a valrubicin, a daunorubicin, a cytarabine, a salt of any of these, or any combination of the foregoing.
19. 13. The method of claim 7, wherein the taxane comprises a paclitaxel, a docetaxel, a cabazitaxel, a salt of any of these, or any combination of the foregoing.
20. 14. The method of claim 7, wherein the mTOR and/or AKT targeting therapy comprises a rapamycin, AZD 8055, a sirolimus, a temsirolimus, an everolimus, a ridaforolimus, a deforolimus, an apitolisib, MK-2206, a afuresertib, a KRX-0401, a Honokiol, a Torinl, a PP242, a PP30, a Ku-0063794, a WAY-600, a WYE-687, a WYE-354, an INK128, an AZD8055, an OSI-02, a salt of any of these, or any combination of the foregoing.

Description

CANNABINOIDS FOR THE TREATMENT OF CANCER CROSS REFERENCE TO RELATED APPLICATIONS [0001] The present disclosures claims priority to U. S. Application No. 63/713,700, filed on 30 October 2024, the contents of which is incorporated herein in its entirety. BRIEF SUMMARY [0002] Provided herein are compositions, methods, and systems comprising a cannabidiol (CBD) or a salt thereof, a terpene or a salt thereof, and/or flavonoids and uses thereof. Compositions, systems, and methods provided herein leverage the composition for the treatment of diseases such as reproductive cancers. Accordingly, in one aspect, provided herein compositions, methods, and systems comprising a cannabidiol (CBD) or a salt thereof, a terpene or a salt thereof, and/or flavonoids for the treatment of cancer which synergize with standard of care cancer treatments [0003] Provided herein are methods for treating an endometrial cancer in a subject in need thereof comprising administering to the subject in need thereof an effective amount of a formulation comprising: a cannabidiol (CBD), or a salt thereof; a terpene, a salt thereof, a flavonoid, a salt thereof, or any combination thereof; a cancer therapeutic; and an excipient, a carrier, a diluent, or any combination thereof. In some embodiments, the endometrial cancer can comprise an endometrial adenocarcinoma, a uterine carcinoma, a uterine sarcoma, a squamous cell carcinoma, a small cell carcinoma, a transitional carcinoma, a serous carcinoma, a clear cell carcinoma, or any combination thereof. In some embodiments, the endometrial cancer can comprise an endometrial adenocarcinoma. In some embodiments, the endometrial cancer can comprise a clear cell carcinoma. In some embodiments, the terpene or salt thereof can comprise a P-myrcene, a P-caryophyllene, an ocimene, an a-pinene, an a-humulene, a linalool, a p-cymene, a camphene, a cis-nerolidol, a terpinolene, an isopulegol, a caryophyllene oxide, a 6-limonene, a geraniol, a guaiol, a-bisabolol, a 3-carene, a P-pinene, a y-terpinene, a salt of any of these, or any combination thereof. In some embodiments, the flavonoid or the salt thereof can comprise a naringenin, a naringin, a blumeatin, a butin, an eriodictyol, a hesperetin, a hesperidin, a homoeriodictyol, an isosakuranetin, a pinocembrin, a poncirin, a sakuranetin, a sakuranin, a sterubin, a pinostrobin, a salt of any of these, or any combination thereof. In some embodiments, the cancer therapeutic can comprise a chemotherapy, an non-steroidal anti-inflammatory (NSAID), a platinum analogue, a tyrosine kinase inhibitor, an anthracycline, a taxane, a mTOR and/or AKT targeting therapy, a p53 targeting therapy, a PARP inhibitor, a sphingolipid metabolism targeting therapy, a hormone therapy, a hyperthermia therapy, an immunotherapy, a photodynamic therapy, a radiation therapy, a stem cell therapy, a surgery, or any combination thereof. In some embodiments, the chemotherapy can comprise a 5 -fluorouracil, a temozolamide, a 6-mercaptopurine, an azacitidine, a capecitabine, a cladribine, a clofarabine, a cytarabine, a decitabine, a floxuridine, a fludarabine, a gemcitabine, a hydroxyurea, a methotrexate, a nelarabine, a pemetrexed, a pentostatin, a pralatrexate, a thioguanine, a trifluridine/tipiracil, a cabazitaxel, a docetaxel, a nab-paclitaxel, a paclitaxel, a vinblastine, a vincristine, a vincristine liposomal, a vinorelbine, a salt of any of these, or any combination thereof. In some embodiments, the NSAID can comprise an ibuprofen, a naproxen, a diclofenac, a celecoxib, a mefenamic acid, an etoricoxib, an indomethacin, an aspirin, a ketorolac, a diclofenac, a meloxicam, a ketorolac, an esomeprazole, a nabumetone, a indomethacin, a mefenamic acid, a piroxicam, a diclofenac, a diflunisal, a sulindac, a ketoprofen, a tolmetin, a fenoprofen, a salt of any of these, or any combination thereof. In some embodiments, the platinum analogue can comprise an eloxatin, a cisplatin, a carboplatin, an oxaliplatin, a nedaplatin, a lobaplatin, a heptaplatin, a triplatin tetranitrate, a phenathriplatin, a picoplatin, a satraplatin, a salt of any of these, or any combination thereof. In some embodiments, the tyrosine kinase inhibitor can comprise a dasatinib, an imatinib, a gefitinib, an erlotinib, a vemurafenib, a sorafenib, a ponatinib, a nilotinib, a masitinib, an axitinib, a pazopanib, a sunitinib, a salt of any of these, or any combination thereof. In some embodiments, the anthracycline can comprise an adriamycin, a caelyx, a cerubidine, a cytarabine, a daunorubicin, a doxorubicin, an epirubicin, a idarubicin, a mitoxantrone, a pharmorubicin, a valrubicin, a daunorubicin, a cytarabine, a salt of any of these, or any combination thereof. In some embodiments, the taxane can comprise a paclitaxel, a docetaxel, a cabazitaxel, a salt of any of these, or any combination thereof. In some embodiments, the mTOR and/or AKT targeting therapy can comprise a rapamycin, AZD 8055, a sirolimus, a temsirolimus, an ev